Yes, still swinging CTIX. Tried to pick some up on todays dip but they missed me. Pressure on bio's next week imo so we'll see if they let me pick some up. Actually thinking next week will be more of a wash psychologically since it's both the last week of "sell in May" and "Looking forward to June & beyond". Should be interesting. Sorry I couldn't post here during the day, phone is too slow.
BooDog wasn't you that followed CBAY? I am interested but have to do researches on it.... (I posted teh charts few posts back) why don't you give up work, you make plenty $$$$.... miser spend some
Kosta how you doing? still trading I see... so you must have done some home work I haven't had much time to talk to you ..... next week it should be better have you got anything interesting? take care ciao
new entry on my lists HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The companys products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. read more>> https://finance.yahoo.com/quote/HTGM/profile?p=HTGM closed well although the volumes of the big days were missing DD
Zosano Pharma Corp is a clinical stage specialty pharmaceutical company. It develops a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of various indications. Zosano Pharma Corp has a market cap of $58.400 million; its shares were traded at around $1.49 . insider buy Interim CEO of Zosano Pharma Corp (ZSAN) John Peter Walker bought 73,716 shares of ZSAN on 05/25/2017 at an average price of $1.36 a share. The total cost of this purchase was $100,254. CEO Recent Trades Interim CEO John Peter Walker bought 73,716 shares of ZSAN stock on 05/25/2017 at the average price of $1.36. The price of the stock has increased by 9.56% since. Interim CEO John Peter Walker bought 73,716 shares of ZSAN stock on 05/25/2017 at the average price of $1.36. The price of the stock has increased by 9.56% since. CFO Recent Trades: CFO and Chief Business Officer Georgia Erbez bought 68,000 shares of ZSAN stock on 05/25/2017 at the average price of $1.32. The price of the stock has increased by 12.88% since
posted here more info >>> https://stockaholics.net/threads/squadra-azzurra-daily-thread-italian.4618/page-10 CytRx Corporation (CYTR) 0.73+0.12 (+19.91%) At close: May 26 4:00PM EDT
Hi Ciao I'm doing good, but you do definitely better in Monaco Frady wasn't my day took some fake breakouts but working on that
CORI look interesting ... I need DD (I don't know the stocks) Day's Range 6.86 - 7.4052 52 Week Range 2.67 - 8.33 Volume 264,776 Avg. Volume 157,922 resist on 7.40 see what will start tomorrow ... it can move with small volume (small cap) woulda been interesting few weeks ago under $5
Kosta tell me more regarding CORI have you traded before? but AEZS I wouldn't touch it ( or just a very quick scalp) JMHO
Spoiler: Insider Trading MENLO PARK, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its underwritten public offering of 5,600,000 shares of common stock at a public offering price of $6.25 per share, with expected gross proceeds to Corium of $35 million. In addition, Corium has granted the underwriters a 30-day option to purchase up to an additional 840,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares will be offered and sold by Corium. The offering is expected to close on May 31, 2017, subject to customary closing conditions. 7 support No I didn't trade it yet but maybe tomorrow
To entice buyers to participate in the secondary offering, companies typically offer to sell their shares at a discount to the current market value. Because buyers and sellers on the open market are aware of the secondary offering, the price they're willing to pay for the shares usually falls in line with the amount of the discount. Kosta watch out the offering ... the price should adjust accordingly .. don't buy higher jmo public offering of 5,600,000 shares of common stock at a public offering price of $6.25 per share,
'morning today I will start with those mentioned on my few last posts.... adding IMMU ZSAN CERS HTGM got few that I would like to do a further DD before posting them,,,,, no time now.... shortly going to collect the cherry ..
shares of Immunomedics (IMMU) were up 4% to $7.77 in premarket trading on Friday. Cowen has started coverage of the Morris Plains, N.J.-based firm at outperform and a $15 price target. In a note on Friday, Cowen analyst Phil Nadeau wrote that Immunomedics' lead candidate, IMMU-132, "has produced compelling Ph. II data in the treatment of relapsed/refractory mTNBC and our physician consultants expect IMMU-132 to become part of the standard of care." "We project a FY2019 launch, and that IMMU-132 will achieve $720MM in worldwide revenue in mTNBC by 2025," Nadeau added. He also noted that IMMU-132 "has shown activity in other tumor types including lung and urothelial, and Immunomedics will soon define a strategy for development in these other cancers."
I posted a lot regarding IMMU (one of my favorite scalping stocks with few good swings) Friday did the 52 wk high + double the av volume.... closing 7.72+0.25 (+3.35%) Day's Range 7.31 - 7.97 52 Week Range 1.95 - 7.97 Volume 6,340,511 Avg. Volume 3,411,588 resist. 7.97 -9.31 pivot 7.26 sup. 6.16 as usual do your own DD .. it could go down as much as up
